Cofinimmo Valuation

Is COFB undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of COFB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: COFB (€66.1) is trading below our estimate of fair value (€92.19)

Significantly Below Fair Value: COFB is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for COFB?

Other financial metrics that can be useful for relative valuation.

COFB key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue13.7x
Enterprise Value/EBITDA19.2x
PEG Ration/a

Price to Sales Ratio vs Peers

How does COFB's PS Ratio compare to its peers?

The above table shows the PS ratio for COFB vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average9.9x
AHR American Healthcare REIT
2x9.5%US$3.9b
AED Aedifica/SA
8.9x3.9%€3.0b
NHI National Health Investors
11.5x13.3%US$3.8b
C2PU Parkway Life Real Estate Investment Trust
17.1x3.2%S$2.5b
COFB Cofinimmo
6.4x0.03%€2.5b

Price-To-Sales vs Peers: COFB is good value based on its Price-To-Sales Ratio (6.4x) compared to the peer average (9.9x).


Price to Earnings Ratio vs Industry

How does COFB's PE Ratio compare vs other companies in the Global Health Care REITs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a0%
n/an/an/a
No. of CompaniesPS048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a0%
n/an/an/a
No more companies

Price-To-Sales vs Industry: COFB is good value based on its Price-To-Sales Ratio (6.4x) compared to the Global Health Care REITs industry average (7.1x).


Price to Sales Ratio vs Fair Ratio

What is COFB's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

COFB PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio6.4x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate COFB's Price-To-Sales Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst COFB forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€66.10
€72.21
+9.3%
6.2%€77.00€60.00n/a14
Sep ’25€62.15
€70.36
+13.2%
7.0%€77.00€60.00n/a14
Aug ’25€61.35
€71.14
+16.0%
8.1%€80.00€60.00n/a14
Jul ’25€57.55
€72.44
+25.9%
6.7%€80.00€60.00n/a14
Jun ’25€60.25
€72.31
+20.0%
8.2%€80.00€60.00n/a14
May ’25€63.40
€72.39
+14.2%
8.2%€80.00€60.00n/a14
Apr ’25€58.35
€72.74
+24.7%
8.2%€80.00€60.00n/a14
Mar ’25€58.30
€73.53
+26.1%
7.1%€80.00€60.00n/a14
Feb ’25€65.90
€74.03
+12.3%
7.2%€82.00€60.00n/a14
Jan ’25€71.50
€74.25
+3.8%
7.7%€85.00€62.00n/a14
Dec ’24€64.60
€74.89
+15.9%
8.9%€87.00€62.00n/a14
Nov ’24€58.85
€75.46
+28.2%
9.6%€87.00€62.00n/a13
Oct ’24€64.10
€82.27
+28.3%
12.7%€102.00€68.00€67.2013
Sep ’24€71.85
€86.69
+20.7%
12.9%€105.00€68.00€62.1513
Aug ’24€71.70
€89.96
+25.5%
11.6%€105.00€68.00€61.3513
Jul ’24€67.65
€90.86
+34.3%
9.3%€105.00€75.00€57.5511
Jun ’24€72.65
€91.77
+26.3%
10.1%€105.00€75.00€60.2511
May ’24€84.35
€93.05
+10.3%
11.5%€110.00€75.00€63.4011
Apr ’24n/a
€93.05
0%
11.5%€110.00€75.00€58.3511
Mar ’24n/a
€95.18
0%
10.9%€110.00€75.00€58.3011
Feb ’24€84.05
€101.09
+20.3%
20.2%€155.00€75.00€65.9011
Jan ’24€84.30
€110.59
+31.2%
20.4%€155.00€80.00€71.5011
Dec ’23€83.00
€110.95
+33.7%
20.2%€155.00€80.00€64.6011
Nov ’23€86.95
€122.50
+40.9%
16.8%€155.00€87.00€58.8511
Oct ’23€84.95
€126.59
+49.0%
15.9%€155.00€87.00€64.1011

Analyst Forecast: Target price is less than 20% higher than the current share price.


Discover undervalued companies